<table>
<tr>
<th>M Category</th>
<th>M Criteria</th>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
</table>  
<!-- PageNumber="9" -->
<!-- PageBreak -->  
<!-- PageNumber="108" -->
<!-- PageHeader="American Joint Committee on Cancer . 2017" -->  
<figure>
<figcaption>Fig. 9.2 Differences in defining criteria between the 7th Edition and
the 8th Edition for staging of NPC: (a) changing the extent of soft tissue
involvement as T2 and T4 criteria. Abbreviation: CS=carotid space,
LP=lateral pterygoid muscle, M =masseter muscle, MP =medial ptery-</figcaption>  
a  
O  
b  
M  
TS  
T  
M  
?  
LP  
MP  
LP  
PV  
W  
PPS  
PC  
CS  
CS  
PC  
II  
1A  
1B  
Caudal border of
cricoid cartilage  
III  
VA  
VB  
IV  
Current 7th Edition  
Proposed 8th Edition  
T2  
T2  
T4  
T4  
</figure><table>
<tr>
<th>When T is ...</th>
<th>And N is ...</th>
<th>And M is ...</th>
<th>Then the stage group is ...</th>
</tr>
<tr>
<td>Tis</td>
<td>NO</td>
<td>M0</td>
<td>0</td>
</tr>
<tr>
<td>T1</td>
<td>NO</td>
<td>M0</td>
<td>I</td>
</tr>
<tr>
<td>T1, TO</td>
<td>N1</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>T2</td>
<td>NO</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>T2</td>
<td>N1</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>T1, TO</td>
<td>N2</td>
<td>MO</td>
<td>III</td>
</tr>
<tr>
<td>T2</td>
<td>N2</td>
<td>M0</td>
<td>III</td>
</tr>
<tr>
<td>T3</td>
<td>NO</td>
<td>MO</td>
<td>III</td>
</tr>
<tr>
<td>T3</td>
<td>N1</td>
<td>M0</td>
<td>III</td>
</tr>
<tr>
<td>T3</td>
<td>N2</td>
<td>M0</td>
<td>III</td>
</tr>
<tr>
<td>T4</td>
<td>NO</td>
<td>MO</td>
<td>IVA</td>
</tr>
<tr>
<td>T4</td>
<td>N1</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>T4</td>
<td>N2</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>IVB</td>
</tr>
</table>  
goid muscle, PG=parotid gland, PPS =parapharyngeal space, PV =pre-
vertebral muscle, T=temporalis muscle, (b) replacing supraclavicular
fossa (blue) by lower neck, i.e., below caudal border of cricoid cartilage
(red) as N3 criteria. From Pan et al.,27 with permissionNoneA grading system is not used for NPCs.The World Health Organization (WHO) classification sys-
tem33 is recommended for histopathologic classification, and
the following histopathologic types are covered by the stag-
ing system (Table 9.1).  
<!-- PageBreak -->  
<!-- PageNumber="109" -->
<!-- PageHeader="9 Nasopharynx" -->  
<table>
<caption>Table 9.1 Classification of NPC</caption>
<tr>
<th>WHO classification</th>
<th>Former terminology</th>
</tr>
<tr>
<td>Keratinizing squamous cell carcinoma</td>
<td>WHO Type I (squamous cell carcinoma)</td>
</tr>
<tr>
<td>Nonkeratinizing carcinoma Differentiated</td>
<td>WHO Type II (transitional cell carcinoma)</td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>WHO Type III (lymphoepithelial carcinoma)</td>
</tr>
<tr>
<td>Basaloid squamous cell carcinoma</td>
<td>No synonym exists (recently described)</td>
</tr>
</table>